The global biodefense market is expected to reach a valuation of US$ 32.99 billion by 2033, up from US$ 16.31 billion in 2023. Over the course of the analysis period, a compound annual growth rate (CAGR) of 7.3% is projected for this market. Businesses will have more opportunities to expand and enter new markets due to the rising demand for pharmaceuticals, immunisations, and medical devices.
Countries must maintain a constant supply of vaccines and biothreat detection technology to ensure their citizens’ safety. Initiatives like these can accelerate the growth of the biodefense industry.
A combination of government initiatives, increased government attention, and funding for biodefense strategies help fuel the biodefense market. As a result, these agents can cause social and economic turmoil. To protect warfighters from novel biological agents, the Department of Defense is modernizing its medical countermeasures approach.
Get a Sample Copy of the Report :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16664
The scope of the biodefense market may be further expanded by increasing private investment. This is due to the occurrence of different viruses such as the flu, the Ebola virus, and the Zika virus. Says a lead analyst at Future Market Insights.
Key Takeaways:
•The biodefense market is anticipated to expand at a CAGR of 7.3% over the forecast period.
•According to estimates, the biodefense market in North America is going to remain strong and account for 79% of the market share throughout the length of the forecast period.
•China is expected to secure a high rate of 8.8% due to surges in research and development.
•The anthrax segment held a significant market share of 28.1% in 2023.
Competitive Landscape:
Several prominent companies dominate this market, including Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc. and others.
Many players are collaborating with governments in emerging and economically advantageous regions to gain bulk orders and boost sales. Key manufacturers are strengthening their presence in the market and staying ahead of the competition through expansion, new product launches, and approvals.
Recent Developments:
•A biodefense vaccine candidate developed by Appili Therapeutics Inc., ATI-1701, is expected to prevent Francisella tularensis infection by the end of February 2022 for over US$ 10 million. This funding may boost the company’s market share and growth in the biodefense market.
•In an announcement, Emergent BioSolutions Inc. announced that its Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) had been approved by the United States Food and Drug Administration (FDA).
•Ichor Medical Systems, Inc., a privately held company, announced in March 2019 that it had entered into a collaboration and research license agreement with AstraZeneca to develop plasmid DNA constructs (recombinant monoclonal antibodies) for clinical testing. The terms of the agreement also include development milestone payments in addition to upfront and annual payments for Ichor.
•In August 2018, CEPI (Coalition for Epidemic Preparedness Innovations) announced a collaboration with Profectus BioSciences, Inc. A vaccine against the Lassa virus was manufactured by Emergent BioSolutions Inc. By collaborating, these companies were able to expand their product portfolios and increase sales.
Biodefense Market Segmentation by Category
By Product:
•Anthrax
•Smallpox
•Botulism
•Radiation/Nuclear
By Region Outlook:
•North America
•Latin America
•Europe
•The Middle East and Africa
•East Asia
Unleash Potential: Craft Your Customized Report Now:
https://www.futuremarketinsights.com/customization-available/rep-gb-16664
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
